has concentrated its investments in BioMarin, an integrated business in the analytical, diagnostic and therapeutic applications of
carbohydrate active enzymes. Glyko Biomedical's principal asset is its 32.7% ownership of BioMarin's outstanding capital stock.
As a result of the sale of Glyko, Inc., the company's principal asset is its 41.7% interest in BioMarin, now an integrated business in the analytical, diagnostic and therapeutic applications of
carbohydrate active enzymes.